SEP 13, 2021 3:00 AM PDT

Fat Loss can Predict Gastric Cancer Survival

WRITTEN BY: Katie Kokolus

Cancer cachexia is a metabolic disorder in cancer patients experiencing uncontrolled weight loss.  While cancer cachexia occurs in all cancer types, it is most common in pancreatic, gastro-oesophageal, head and neck, lung, and colorectal cancers. 

There is a very high rate of cancer cachexia for patients nearing the end of life, but it also arises in smaller frequencies in patients with curable cancers.  While nutritional interventions are ineffective at treating cachexia in cancer patients, successful treatment of the underlying cancer can reverse the symptoms. 

Cancer cachexia correlates to poor overall survival, and this subset of patients are less responsive to cancer therapies, including chemotherapy

One of the major drivers of cancer cachexia is adipose tissue loss.  There are two major types of adipose tissues, white and brown.  White adipose tissue, fatty tissue responsible for storing energy within the body for use by other organs, contains subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT). 

SAT is located throughout the body beneath the skin, and VAT is concentrated around the abdomen.  While VAT is linked to other metabolic syndromes, including insulin resistance and diabetes, the contribution of SAT and VAT to the development of cancer cachexia is not well understood.

A recent study published in Clinical Nutrition investigated the contributions of SAT and VAT in gastric cancer patients with cachexia.  The study enrolled over 1600 gastric cancer patients, including 411 with cachexia and 1216 without cachexia.  Patients received a CT scan that the research team used to measure SAT and VAT around the L3 vertebra.  Calculations made from these scans determined the areas of SAT and VAT following normalization for patient height. 

The researchers found that SAT was significantly lower in cancer patients with cachexia than non-cachexia patients.  Further, among the cachexia patients, low SAT correlated with poor survival.

The study found no difference in VAT between the cachexia and non-cachexia patients, nor was there any effect of VAT on survival. 

This study confirms that adipose tissues loss is a key feature of cachexia among gastric cancer patients.  Additionally, the study demonstrates that SAT, but not VAT, is a driving factor of cachexia in this cohort of patients.  The authors propose the use of SAT as a prognostic factor for cachexic gastric cancer patients. 

 

Sources: Cancer cachexiacommonchemotherapyadipose tissueClinical Nutrition

About the Author
  • PhD in Tumor Immunology. I am interested in developing novel strategies to improve the efficacy of immunotherapies used to extend cancer survivorship.
You May Also Like
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
OCT 12, 2021
Immunology
Cancer Drug Helps Alzheimer's Mice Remember
OCT 12, 2021
Cancer Drug Helps Alzheimer's Mice Remember
What if a drug—specifically developed to treat one disease—had the potential to address other non-related co ...
NOV 04, 2021
Cancer
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
NOV 04, 2021
Giving the Immune System a Kickstart to Improve Immunotherapy Efficacy
Despite the incremental success immune checkpoint inhibitors (ICI) have attributed to the cancer treatment landscape rec ...
DEC 16, 2021
Cancer
Age Matters! Young Adults May Need Different Cancer Therapies
DEC 16, 2021
Age Matters! Young Adults May Need Different Cancer Therapies
The incidence of various cancers, including multiple myeloma, colorectal, kidney, and pancreatic cancer, is steadily&nbs ...
JAN 07, 2022
Cancer
Crossing the Blood-Brain Barrier: Improving Experimental Models to Study Drug Delivery
JAN 07, 2022
Crossing the Blood-Brain Barrier: Improving Experimental Models to Study Drug Delivery
The blood-brain barrier (BBB) describes the complex vasculature network that delivers oxygen and nutrients to the brain. ...
JAN 07, 2022
Drug Discovery & Development
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
JAN 07, 2022
The genetic testing company 23andMe begins phase 1 clinical trial for cancer drug
This week, 23andMe, the consumer genetic testing giant, announced that it has begun a phase 1 clinical trial o ...
Loading Comments...